CHARLES BRAIN

H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 1994, the Setting Every Community Up for Retirement Enhancement (SECURE) Act of 2019, provisions to expand opportunities to increase retirement savings and improve the portability of lifetime income options from one plan to another. Legislation to enhance retirement plan options

Legislation to enhance retirement plan options H.R. 1994--Setting Every Community Up for Retirement Enhancement (SECURE) Act of 2019.

H.R. 1994, the Setting Every Community Up for Retirement Enhancement (SECURE) Act of 2019, provisions to expand opportunities to increase retirement savings and improve the portability of lifetime income options from one plan to another. H.R.5282/S.2526, Retirement Enhancement and Savings Act, provisions encouraging workers to save more for retirement, small employer retirement plan coverage, worker participation and education, and facilitates guaranteed lifetime income in retirement.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.

The American Innovation Act, proposed legislation on the preservation of start-up NOLS and tax credits. Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures, Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers, S. 617, Tax Extender and Disaster Relief Act of 2019, legislation to amend the Internal Revenue Code of 1986 to extend certain expiring provisions

The American Innovation Act, proposed legislation on the preservation of start-up NOLS and tax credits. Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures, Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers, S. 617, Tax Extender and Disaster Relief Act of 2019, legislation to amend the Internal Revenue Code of 1986 to extend certain expiring provisions

H.R. 1994, the Setting Every Community Up for Retirement Enhancement (SECURE) Act of 2019, provisions to expand opportunities to increase retirement savings and improve the portability of lifetime income options from one plan to another. H.R.5282/S.2526, Retirement Enhancement and Savings Act, provisions encouraging workers to save more for retirement, small employer retirement plan coverage, worker participation and education, and facilitates guaranteed lifetime income in retirement.

H.R. 1994, the Setting Every Community Up for Retirement Enhancement (SECURE) Act of 2019, provisions to expand opportunities to increase retirement savings and improve the portability of lifetime income options from one plan to another. H.R.5282/S.2526, Retirement Enhancement and Savings Act, provisions encouraging workers to save more for retirement, small employer retirement plan coverage, worker participation and education, and facilitates guaranteed lifetime income in retirement.

Technical fixes to HR 1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018; provisions to enhance retirement plan options

Technical fixes to HR 1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018; provisions to enhance retirement plan options

Technical fixes to HR 1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018; provisions to enhance retirement plan options

Issues related to the passage of comprehensive Tax Reform Legislation, H.R.1.

Technical fixes to HR 1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018; provisions to enhance retirement plan options

Issues related to the passage of comprehensive Tax Reform Legislation, H.R.1.

Issues related to the passage of comprehensive Tax Reform Legislation, H.R.1.

Issues related to the passage of comprehensive Tax Reform Legislation, H.R.1.

H.R. 1624 - Municipal Finance Support Act Issues related to Custodial Banking and Supplemental Leverage Ratio

H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage. H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.

H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). H.R. 3921, Healthy Kids Act, a bill to extend funding for the Children's Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. Issues dealing with value-based contracts. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage. H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). H.R. 3921, Healthy Kids Act, a bill to extend funding for the Children's Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. Issues dealing with value-based contracts. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB). H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act Legislation to address opioids manufacturing and distribution Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act, potential provisions relating to legislatively extending Cost Sharing Reduction payments to insurers H.R. 4225/S. 2241, A bill amends the Patient Protection and Affordable Care Act to prohibit a state from funding its health insurance exchange by charging a health insurer a fee or tax for excepted benefits coverage (benefits not subject to requirements under the Act) or standalone dental plans that are not sold on an exchange.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act. S. 469, Affordable and Safe Prescription Drug Importation Act. H.R. 6, legislation to address opioids manufacturing and distribution. Pandemic and All-Hazards Preparedness Re-authorization Act (PAHPRA), vaccines and other various provisions.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act H.R. 6Legislation to address opioids manufacturing and distribution Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act H.R. 6, Legislation to address opioids manufacturing and distribution Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act, potential provisions relating to legislatively extending Cost Sharing Reduction payments to insurers

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act. S. 469, Affordable and Safe Prescription Drug Importation Act. H.R. 6, legislation to address opioids manufacturing and distribution. Pandemic and All-Hazards Preparedness Re-authorization Act (PAHPRA), vaccines and other various provisions.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act H.R. 6, Legislation to address opioids manufacturing and distribution Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act. S. 469, Affordable and Safe Prescription Drug Importation Act. H.R. 6, legislation to address opioids manufacturing and distribution. Pandemic and All-Hazards Preparedness Re-authorization Act (PAHPRA), vaccines and other various provisions.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act, potential provisions relating to legislatively extending Cost Sharing Reduction payments to insurers H.R. 4225/S. 2241, A bill amends the Patient Protection and Affordable Care Act to prohibit a state from funding its health insurance exchange by charging a health insurer a fee or tax for excepted benefits coverage (benefits not subject to requirements under the Act) or standalone dental plans that are not sold on an exchange.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act.

H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act. S. 469, Affordable and Safe Prescription Drug Importation Act. Legislation to address opioids manufacturing and distribution. Pandemic and All-Hazards Preparedness Re-authorization Act (PAHPRA), vaccines and other various provisions.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage. Issues related to insulin pricing.

H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.

CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. Issues dealing with value-based contracts. H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. Issues dealing with value-based contracts. H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.

H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage. Issues related to insulin pricing.

H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage. H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.

H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference. H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data. H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.